ArticleJournal for immunotherapy of cancer2024
Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer.
Article in Journal for immunotherapy of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Integrated immunophenotypic and ProMisE molecular profiling as predictors of immune checkpoint inhibitor response in recurrent endometrial cancer.Cancer immunology, immunotherapy : CII · 2026Article
- Recurrent Distant Metastatic Endometrial Cancer Treated with Immunotherapy with Pembrolizumab: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
- IMPDH1 is a potential immune evasion-related oncoprotein in endometrial cancer.BMC genomic data · 2026Article
- Review
- An interpretable deep learning model for predicting endometrial cancer molecular subtypes from H&E-stained slides.NPJ precision oncology · 2026Article
- Predictive biomarkers for immunotherapy response in endometrial cancer: current insights and future directions.Exploration of targeted anti-tumor therapy · 2026Review
- Integrating chemokine signatures and multi-omic biomarkers to predict immunotherapy response in non-small cell lung cancer: a comprehensive narrative review.Frontiers in oncology · 2026Review
- The dysregulation of the immune microenvironment during endometrial intraepithelial neoplasia serves as a marker of endometrial carcinogenesis.Frontiers in immunology · 2026Review
- Endometrial carcinoma and immune escape: prognostic relevance of HLA class I loss in NSMP subtype.Histopathology · 2026Article
- Uterine Stroma-Derived Tumors and the Extracellular Matrix: A Comparative Review of Benign and Malignant Pathologies.Cancers · 2025Review
- Epigenetic regulation in gynecological cancers: a paradigm shift in immunotherapy strategies.Journal of experimental & clinical cancer research : CR · 2025Review
- Microsatellite instability and PD-L1 expression in sarcomas: current evidence and clinical perspectives.Medical oncology (Northwood, London, England) · 2025Review
- Tumor-Infiltrating Lymphocytes in Breast and Female Genital Tract Cancers: Overlooked Potential and Unexplored Frontiers.Cancer medicine · 2025Review
- Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers.Nature reviews. Clinical oncology · 2025Review
- The dual nature of immunotherapy in female reproductive disorders: immune homeostasis and clinical challenges.Frontiers in immunology · 2025Review
- Single-cell technologies and spatial transcriptomics: decoding immune low - response states in endometrial cancer.Frontiers in immunology · 2025Review
- Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment.Cancers · 2024Review
- Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with mismatch repair-deficient (MMRd) endometrial cancer (EC) can derive great benefit from immune checkpoint inhibitors (ICI). However not all responses and predictors of primary resistance are lacking.
methodsWe compared the immune tumor microenvironment of MMRd EC ICI-responders (Rs) and ICI non-responders (NRs), using spatial multiplexed immune profiling and unsupervised hierarchical clustering analysis.
resultsOverall, NRs exhibited drastically lower CD8
conclusionsThese findings underscore the potential of immune tumor microenvironment features for identifying patients with MMRd EC and primary resistance to ICI who should be oriented towards trials testing novel immunotherapeutic combinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.